How Do We Treat Patients With Advanced Hepatocellular… : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
o achieve positive outcomes despite having risk factors, known as positive deviants, may help identify protective characteristics and decrease health disparities among this growing population…
An abstract is unavailable.
The fellowship provides a two-year grant of $130,000 to support the salary and benefits of the fellow while working on a mentored brain cancer research…
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Since the addition of rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), major advances in first-line therapy of large B-cell
Research and Education Fund Tiered Giving The Research and Education Fund (REF) Tiered Giving Program recognizes donors whose contributions since 2014 have collectively advanced cancer…
Experts examine both overall survival outcomes and independent review committee–assessed progression-free survival data from the AMPLIFY trial.
Efficacy findings from a phase 2 trial demonstrated that abenacianine visualized lung tumor tissue and was well tolerated when used during surgery.
The prevalence of metabolic syndrome among adult survivors of childhood cancer is higher compared to a noncancer control population. Therapeutic exposures and lifestyle factors are…
Study results “provide strong support for integrating symptom screening and care pathways into routine clinical care,” according to researchers